Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)

120.83
Delayed Data
As of Feb 20
 -2.05 / -1.67%
Today’s Change
45.00
Today|||52-Week Range
147.63
-4.90%
Year-to-Date

Today’s Trading

Previous close122.88
Today’s open121.62
Day’s range120.13 - 123.77
Volume396,096
Average volume (3 months)1,091,304
Market cap$12.3B
Data as of 4:00pm ET, 02/20/2018

Growth & Valuation

Earnings growth (last year)-13.15%
Earnings growth (this year)--
Earnings growth (next 5 years)+163.00%
Revenue growth (last year)+90.66%
P/E ratioNM
Price/Sales127.96
Price/Book6.93

Competitors

 Today’s
change
Today’s
% change
ALKSAlkermes Plc-2.51-3.73%
SGENSeattle Genetics Inc-0.32-0.59%
TSROTESARO Inc+2.30+3.83%
JAZZJazz Pharmaceuticals...-0.98-0.67%
Data as of 4:00pm ET, 02/20/2018

Financials

Last reporting dateFebruary 8, 2018
EPS forecast (this quarter)-$1.38
Annual revenue (last year)$89.9M
Annual profit (last year)-$490.9M
Net profit margin-545.95%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
John M. Maraganore
President
Barry E. Greene
Corporate headquarters
Cambridge, Massachusetts

Forecasts